Related Experiment Video
Updated: May 17, 2026
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Moderate aplastic anemia in children: preliminary outcomes for treatment versus observation from a
Katharine Brock1, Neil Goldenberg, Douglas K Graham
1Department of Pediatrics, University of Colorado, Aurora, CO, USA.
Introduction:
Because of the variety of definitions used to describe moderate aplastic anemia (MAA), we review our institutional experience period with patients who met a proposed set of criteria for this disorder. On an exploratory basis, we sought to evaluate the influence of treatment with immunosuppressive therapy (IST) versus observation on long-term outcomes.
Materials And Methods:
Records from 1999 to 2010 were screened for patients who met the criteria for MAA: (1) bone marrow cellularity of 20% to 50%; (2) cytopenias in at least 1 cell line (absolute neutrophil count<1000/µL, hemoglobin<9 g/dL, platelet count<100,000/µL); (3) mean corpuscular volume ≥90; (4) persistence >6 months; and (5) negative Fanconi studies. Data were collected for patient/disease characteristics, treatments, and outcomes.
Results:
Eight patients met the criteria for MAA. Three of 8 patients received IST. Of 3 patients who received IST, complete response was observed in 2 and transfusion independence in 1, as compared with 2 of 5 and 3 of 5 in the group who were observed without IST. Median duration of follow-up was 48 months.
Discussion:
As several patients spontaneously resolved, and none developed severe aplastic anemia, acute myelogenous leukemia, or myelodysplastic syndrome, the criteria used here may identify a group of children with favorable prognosis who can be managed supportively.
Insights
This study suggests that specific criteria may identify children with moderate aplastic anemia (MAA) who have a favorable prognosis. Supportive management may be sufficient for these patients, as severe outcomes were not observed.
Area of Science:
- Hematology
- Pediatric Hematology
- Aplastic Anemia Research
Background:
- Moderate aplastic anemia (MAA) lacks a standardized definition, leading to varied diagnostic approaches.
- This study reviews institutional experience with a proposed set of MAA criteria.
- The study explores the impact of immunosuppressive therapy (IST) versus observation on patient outcomes.
Purpose of the Study:
- To evaluate the long-term outcomes of patients meeting specific criteria for moderate aplastic anemia.
- To compare the effectiveness of immunosuppressive therapy (IST) against observation in managing MAA.
- To determine if the proposed MAA criteria identify a patient group with a favorable prognosis.
Main Methods:
- Retrospective review of patient records from 1999 to 2010.
- Inclusion criteria for MAA: bone marrow cellularity 20-50%, specific cytopenias, MCV ≥90, persistence >6 months, negative Fanconi studies.
- Data collected on patient/disease characteristics, treatments (IST vs. observation), and outcomes.
Main Results:
- Eight patients met the defined MAA criteria.
- Two of three patients receiving IST achieved complete response; one gained transfusion independence.
- Two of five observed patients achieved complete response; three gained transfusion independence. Median follow-up was 48 months.
Conclusions:
- The proposed MAA criteria may identify a pediatric subgroup with a favorable prognosis.
- Spontaneous resolution was observed in some patients.
- No patients progressed to severe aplastic anemia, acute myelogenous leukemia, or myelodysplastic syndrome, suggesting supportive management is viable.
Related Concept Videos
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption